Key terms
About FDMT
4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. The firm also offers product candidates focused on large market ophthalmology, pulmonology, and cardiology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest FDMT news
Apr 15
7:20am ET
4D Molecular price target raised to $40 from $35 at RBC Capital
Apr 15
6:55am ET
RBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
Apr 15
4:57am ET
4D Molecular initiated with an Overweight at Barclays
Apr 15
4:30am ET
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)
Apr 01
8:10am ET
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Biogen (BIIB)
Apr 01
7:56am ET
4D Molecular assumed with a Buy at Jefferies
Apr 01
7:12am ET
4D Molecular price target lowered to $63 from $70 at BMO Capital
Mar 29
3:08am ET
Optimistic Outlook for 4D Molecular Therapeutics Ahead of Regulatory Update on CF Gene Therapy 4D-710
Mar 28
8:10am ET
4D Molecular announce update on regulatory interactions, development for 4D-710
Mar 01
7:26am ET
RBC Capital Keeps Their Buy Rating on 4D Molecular Therapeutics (FDMT)
Mar 01
6:35am ET
Buy Rating Affirmed: 4D Molecular Therapeutics’ Innovative Gene Therapy Platform Shows Promising Results in Phase 2 Trials
Feb 15
1:19am ET
Buy Rating Affirmed on 4D Molecular Therapeutics Amid Positive Phase 1/2 INGLAXA Trial Updates and Anticipated Regulatory Advancements
Feb 13
6:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT)
Feb 13
5:15am ET
Strong Buy Recommendation for 4D Molecular Therapeutics Amid Promising 4D-150 Gene Therapy Study Results
Feb 13
4:58am ET
Buy Rating on 4D Molecular Therapeutics Backed by Strong Clinical Results and Broad Commercial Prospects
Feb 12
8:17am ET
4D Molecular presents interim data from 4D-310 INGLAXA Phase 1/2 trials
Feb 10
4:52am ET
4D Molecular Therapeutics Secures Major Financial Deal
Feb 08
9:39am ET
4D Molecular price target raised to $82 from $33 at BofA
Feb 08
6:11am ET
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), BridgeBio Pharma (BBIO) and Phibro Animal Health (PAHC)
Feb 07
10:32am ET
Amgen downgraded, Enphase upgraded: Wall Street’s top analyst calls
Feb 07
8:32am ET
Buy Rating Affirmed for 4D Molecular Therapeutics on Promising Wet AMD Treatment Trial Results
Feb 07
4:45am ET
Positive Outlook for 4D Molecular Therapeutics with Buy Rating Amid Advancements in Gene Therapy
Feb 07
4:38am ET
4D Molecular reinstated with a Buy at Goldman Sachs
Feb 07
1:58am ET
4D Molecular 6.59M share Secondary priced at $29.50
Feb 05
4:39pm ET
4D Molecular files automatic mixed securities shelf
Feb 05
4:06pm ET
4D Molecular announces $250M common stock offering
Feb 05
4:06pm ET
4D Molecular files to sell $250M in common stock
Feb 05
12:28pm ET
4D Molecular price target raised to $70 from $50 at BMO Capital
Feb 05
11:58am ET
4D Molecular cystic fibrosis treatment granted FDA orphan designation
Feb 05
10:15am ET
Buy Rating for 4D Molecular Therapeutics Backed by Promising 4D-150 Gene Therapy Trial Results
Feb 05
9:49am ET
4D Molecular price target raised to $35 from $25 at RBC Capital
No recent press releases are available for FDMT
FDMT Financials
Key terms
Ad Feedback
FDMT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
FDMT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
